Kristina King

Title: Innovations by Kristina King in Pharmaceutical Compositions

Introduction

Kristina King is an accomplished inventor based in Berlin, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of oral contraceptives. With a total of three patents to her name, her work focuses on enhancing the stability and efficacy of pharmaceutical compositions.

Latest Patents

One of her latest patents is a pharmaceutical composition containing a tetrahydrofolic acid. This invention relates to solid pharmaceutical compositions, specifically oral contraceptives, which include a progestogen, such as drospirenone, and an estrogen, such as ethinylestradiol. The composition ensures good stability of the tetrahydrofolic acid during storage while providing a fast and reliable release of the active ingredients.

Another notable patent is a pharmaceutical composition comprising progestogens and/or estrogens along with 5-methyl-(6S)-tetrahydrofolate. This composition serves as an oral contraceptive and addresses disorders caused by folate deficiency, particularly cardiovascular issues and congenital malformations. It facilitates the body's utilization of the folate component, ensuring its biological activity in preventing these malformations.

Career Highlights

Kristina has worked with prominent companies in the pharmaceutical industry, including Bayer Intellectual Property GmbH and Bayer Pharma Aktiengesellschaft. Her experience in these organizations has contributed to her expertise in developing innovative pharmaceutical solutions.

Collaborations

Throughout her career, Kristina has collaborated with notable professionals such as Kai Strothmann and Gavin Welch Wasserfall-Smith. These partnerships have further enriched her work and expanded her impact in the field.

Conclusion

Kristina King's innovative contributions to pharmaceutical compositions demonstrate her commitment to improving health outcomes through science. Her patents reflect a deep understanding of the complexities involved in drug formulation and the importance of addressing health issues related to folate deficiency.